Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Sex Transm Infect ; 95(6): 428-436, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31073094

RESUMEN

BACKGROUND: Men who have sex with men (MSM) are disproportionately affected by HIV and other STIs worldwide. Rectal douching, which is commonly used by MSM in preparation for anal sex, may increase the risk of HIV and other STIs by injuring the rectal mucosa. Results from individual studies reporting associations between rectal douching and HIV and other STIs among MSM are inconsistent. We performed a systematic review and meta-analysis to estimate the association between rectal douching and HIV and other STIs among MSM. METHODS: We searched PubMed, Embase, Scopus and Web of Science for studies published from January 1970 to November 2018. Studies that reported ORs and 95% CIs of associations between rectal douching and infection with HIV/STIs, or reported enough data to calculate these estimates, were included. We assessed risk of bias using the Newcastle-Ottawa Scale. ORs were pooled using a random effects model. RESULTS: Twenty-eight eligible studies were identified in our review, of which 24 (20 398 participants) were included in the meta-analysis. Rectal douching was associated with increased odds of infection with HIV (OR 2.80, 95% CI 2.32 to 3.39), and any STI other than HIV (including hepatitis B virus (HBV), hepatitis C virus (HCV), chlamydia, gonorrhoea, syphilis and human papillomavirus) (OR 2.46, 95% CI 1.95 to 3.11) among MSM. For specific STIs, douching was associated with increased odds of viral hepatitis (HBV, HCV) (OR 3.29, 95% CI 2.79 to 3.87), and chlamydia or gonorrhoea (OR 3.25, 95% CI 2.02 to 5.23). These associations remained significant in studies that adjusted for potential confounders. CONCLUSION: Rectal douching may put MSM at increased risk for infection with HIV and other STIs. Longitudinal studies are needed to clarify this association, and health education materials should inform men of the potential for increased risk of infection with rectal douching.


Asunto(s)
Infecciones por VIH/prevención & control , Homosexualidad Masculina/estadística & datos numéricos , Enfermedades de Transmisión Sexual/prevención & control , Irrigación Terapéutica , Adulto , Estudios de Casos y Controles , Estudios de Cohortes , Infecciones por VIH/epidemiología , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Conducta Sexual , Enfermedades de Transmisión Sexual/epidemiología , Irrigación Terapéutica/efectos adversos , Adulto Joven
2.
Glob Public Health ; 14(1): 152-160, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-29237332

RESUMEN

Traditional, complementary, and alternative medicine (TCAM) has been used by some people living with HIV (PLHIV) in an attempt to cure HIV. This article reviews the main factors influencing their decision to choose TCAM to cure HIV and discusses implications for HIV cure research. Those who decide to pursue traditional, complementary, and alternative medical cures may be influenced by the health system, cultural, and social dynamics, and their own individual beliefs and preferences. These same factors may impact participation in HIV cure research. People who search for traditional, complementary, and alternative medical cures may face special challenges as they are recruited, consented, and retained within HIV cure research studies. To address these potential challenges, we have suggested solutions focusing on culturally tailored communication and education, formative social science research, and community partnerships with key stakeholders. The social conditions that have promoted traditional, complementary and alternative medical cures will likely impact how PLHIV participate and experience HIV remission trials. Despite the potential challenges, it will be crucial to involve those who have previously sought out traditional cures for HIV in HIV cure research.


Asunto(s)
Terapias Complementarias , Infecciones por VIH/prevención & control , Medicina Tradicional , Investigación Biomédica , Humanos
3.
Indian J Med Microbiol ; 36(4): 513-516, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30880698

RESUMEN

BACKGROUNDS: This randomised controlled, open-label, non-inferiority trial was conducted in antiretroviral-naïve HIV-1-infected patients to assess the efficacy and safety of 48-week dual therapy of LPV/r plus 3TC (DT group) compared with Chinese first-line triple-therapy regimen (TT group). METHODS: 198 were randomised to DT (n = 100) or TT (n = 98). RESULTS: Ninety-two DT patients (92%) and 88 TT patients (89.8%) achieved HIV-1 RNA <50 copies/ml at week 48 (P = 0.629). Moreover, the safety profile was similar between two groups, and no secondary HIV resistance was observed. CONCLUSION: The results suggest that dual therapy of LPV/r plus 3TC is non-inferior to the first-line triple-therapy regimen in China.


Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Terapia Antirretroviral Altamente Activa/métodos , Infecciones por VIH/tratamiento farmacológico , VIH-1/aislamiento & purificación , Lamivudine/administración & dosificación , Lopinavir/administración & dosificación , Ritonavir/administración & dosificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Fármacos Anti-VIH/efectos adversos , Terapia Antirretroviral Altamente Activa/efectos adversos , China , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/patología , Femenino , Humanos , Lamivudine/efectos adversos , Lopinavir/efectos adversos , Masculino , Persona de Mediana Edad , Ritonavir/efectos adversos , Resultado del Tratamiento , Carga Viral , Adulto Joven
4.
PLoS One ; 11(6): e0157438, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27341031

RESUMEN

BACKGROUND: The advent of direct-acting agents (DAAs) has improved treatment of HCV in HIV co-infection, but may be limited by primary drug resistance. This study reports the prevalence of natural polymorphisms conferring resistance to NS3/4A protease inhibitors and NS5B polymerase inhibitors in treatment-naïve HIV/HCV co-infected individuals in China. METHODS: Population based NS3/4A sequencing was completed for 778 treatment-naïve HIV/HCV co-infected patients from twelve provinces. NS3 sequences were amplified by nested PCR using in-house primers for genotypes 1-6. NS5B sequencing was completed for genotyping in 350 sequences. Resistance-associated variants (RAVs) were identified in positions associated with HCV resistance. RESULTS: Overall, 72.8% (566/778) of all HCV sequences had at least one RAV associated with HCV NS3/4A protease inhibitor resistance. Variants were found in 3.6% (7/193) of genotype 1, 100% (23/23) of genotype 2, 100% (237/237) of genotype 3 and 92% (299/325) of genotype 6 sequences. The Q80K variant was present in 98.4% of genotype 6a sequences. High-level RAVs were rare, occurring in only 0.8% of patients. 93% (64/69) patients with genotype 1b also carried the C316N variant associated with NS5B low-level resistance. CONCLUSIONS: The low frequency of high-level RAVs associated with primary HCV DAA resistance among all genotypes in HIV/HCV co-infected patients is encouraging. Further phenotypic studies and clinical research are needed.


Asunto(s)
Antivirales/farmacología , Coinfección , Farmacorresistencia Viral , Infecciones por VIH , Hepacivirus/efectos de los fármacos , Hepacivirus/genética , Hepatitis C/virología , Polimorfismo Genético , Proteínas no Estructurales Virales/genética , Adulto , Anciano , Alelos , China , Femenino , Genotipo , Hepatitis C/tratamiento farmacológico , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Fenotipo , Filogenia , Inhibidores de Proteasas/farmacología , Proteínas no Estructurales Virales/antagonistas & inhibidores , Proteínas no Estructurales Virales/química , Adulto Joven
5.
J Colloid Interface Sci ; 453: 244-251, 2015 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-25989055

RESUMEN

Biomimetic self-curled nanoplates assembled coral-like nanoporous γ-Al2O3 has been prepared by a solvothermal method using ethylene glycol (EG)H2O as the mixed solvent, followed by the annealing process. The resulting samples are composed of micro/nanostructured units (∼1.5 µm) with self-curled porous nanoplates on the surface. The volume ratio of EG to water in precursor solution is crucial for the formation of coral-like structure. The formation process is investigated to be an assembly process with self-curled nanoplates driven by adsorption of EG. Importantly, the coral-like porous γ-Al2O3 has high surface area of 64.18 m(2)/g and exhibits enhanced adsorption performance for efficient removal of heavy metal Hg(II) (49.15 mg/g). The removal capacity is higher than (∼2.5 times) those of commercial Al2O3 nanoparticles and hollow structured γ-Al2O3 prepared without EG (∼2.7 times). Further investigation shows adsorption behaviors of the coral-like γ-Al2O3 and the alumina hollow structure can be well described by Langmuir isotherm model, whereas that of commercial Al2O3 nanoparticles fits Freundlich isotherm model. This work not only provides an inspiration for high efficient biomimetic adsorbent but also presents a facile route for coral-like γ-Al2O3 preparation.


Asunto(s)
Óxido de Aluminio/química , Antozoos/química , Materiales Biomiméticos/química , Metales Pesados/aislamiento & purificación , Nanoestructuras/química , Contaminantes Químicos del Agua/aislamiento & purificación , Adsorción , Animales , Biomimética/métodos , Nanoestructuras/ultraestructura , Porosidad , Purificación del Agua/métodos
6.
Asian Pac J Trop Dis ; 5(9): 687-690, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26877974

RESUMEN

There are over 100 clinical trials worldwide focused on developing an HIV cure. Research participants will assume substantial individual risks while receiving little or no individual benefit. Physicians will have important dual roles of leading HIV cure research studies and guiding patient expectations. Many low and middle-income nations have started HIV cure trials, including China. The goal of this study was to better understand physician attitudes, behaviors, and perceptions of HIV cure research within the context of China. We conducted a quantitative and qualitative evidence review of published literature on physician perceptions of HIV cure in China. Quantitative survey data revealed that physicians rarely believed HIV was curable, but this perception may be more common compared to other countries. Qualitative data showed that inconsistent terminology used among physicians may contribute to the perception of HIV as curable. The belief that HIV is curable among some physicians in China may be related to the influence of traditional Chinese medicine beliefs. Rather than seeking elimination of pathogens, traditional Chinese medicine aims to achieve harmony between organs and a vital life force. In this context, HIV infection can be seen as a temporary state of imbalance rather than an irreversible change. There is a wide range of physician perceptions about HIV cure in China. Conflicting information about HIV cure from physicians and other sources could thwart the progress of HIV cure research. Enhancing patient-physician communication about ongoing HIV cure research trials will be important for developing an HIV cure.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA